Direct binding of 1251-Tyr8-bradykinin to a microsomal fraction prepared from rat uterine smooth muscle, showed an apparent dissociation constant (KD) at 29°C of 5.0 x 10-10 M calculated from kinetic studies and 6.6 X 10-10 M from Scatchard plot analysis. The binding of 1251-Tyr8-bradykinin was reversible and saturable , and demonstrated high specificity for Tyr8-bradykinin, bradykinin and Lys-bradykinin, but was not displaced by unrelated peptides angiotensin I, angiotensin II, Arg8-vasopressin and oxytocin. The binding sites were copurified by differential centrifugation and on a discontinuous sucrose density gradient with 5'-nucleotidase activity, a plasma membrane marker enzyme. Prolonged intravenous infusion of bradykinin (5 nmol/h for 2 days) induced a 20% decrease in the number of bradykinin binding sites without a change in the equilibrium dissociation constant. The present results demonstrate that receptors mediating the effect of bradykinin on rat uterine smooth muscle are situated on plasma membranes and the regulation of the receptors is in part under the control of endogenous bradykinin levels. receptor regulation ; myometrial membranes ; 125I-Tyr8-bradykinin ; bradykinin infusion Bradykinin and other kinins modify cardiovascular hemodynamics by influencing vascular smooth muscle tone. The mechanism of action of bradykinin on vascular smooth muscle remains uncertain as characterisation of the bradykinin-receptor interaction has not been fully documented (Odya and Goodfriend 1979) . Receptor binding is the first event in the series of molecular processes leading to hormonal effects in the target tissue and is also important both
for physiological specificity and sensitivity.
The bradykinin-receptor interaction has been characterised by inference from indirect studies using isolated tissues ; Barabe et al. 1977) . These extensive studies of in vitro biological responses to bradykinin and its analogues in rabbit aorta, cat ileum and rat uterus, have provided evidence for the presence of two different types of receptors for bradykinin.
However, these pharmacological experiments do not localize the specific subcellular receptors for this hormone, nor are they capable of identifying specific receptor modifications. In vitro direct binding studies using radiolabeled ligands have the advantages of localizing cellular receptors and of characterising specific receptor parameters. There have been few reports on specific bradykinin direct binding studies using a radiolabeled ligand (Reissmann et al. 1977 ; Odya et al. 1980) .
Rat uterine smooth muscle is the tissue most sensitive in vitro to the agonist effect of bradykinin and possesses very little kininase activity (Stewart 1979 ). Since uterine smooth muscle is a frequently used model of vascular smooth muscle and since it possesses the above two important properties, we have defined the characteristics of receptors for bradykinin using a radiolabeled bradykinin ligand in this tissue.
MATERIALS AND METHODS
Radiolabeled ligands and peptides. Binding studies were performed with monoiodinated bradykinin (125I-Tyr8-bradykinin), prepared by the method of Hunter and Greenwood (1962) . The labeled ligand was purified using Amberlite resin IRA 400 (BDH Chemicals, Poole, England) ion exchange chromatography to remove unreacted 125I and subsequently purified on Sephadex G25 (Pharmacia Fine Chemicals, Sweden) or CM Sephadex C25 (Pharmacia Fine Chemicals, Sweden) to isolate monoiodinated 125I-Tyr8-bradykinin.
The specific activity of 125I-Tyr8-bradykinin determined by the self displacement antibody method (Berson et al. 1964 ) was 100-300 Ci/mmol. 125I-Tyr8-bradykinin retained equal biological activity to the unlabeled Tyr8-bradykinin assessed by the blood pressure dose-response curves in a rat bioassay system. Monoiodination was confirmed by thin layer chromatography (n-butyl alcohol : pyridine : acetic acid : water, 15: 10 : 3: 10). Sodium iodide-125 was supplied from New England Nuclear Corporation (Boston, USA). 3H-Bradykinin with specific activity of 21 Ci/mmol was a gift of Dr . J.L. Morgat (Centre D' Energie Atomique, Department de Biologie, Service de Biochimie, Saclay, France). Synthetic bradykinin, Tyr8-bradykinin, Lys-bradykinin, Met-Lys-bradykinin, Tyr5-bradykinin, Tyr-bradykinin, and des-Arg9-bradykinin were obtained from Protein Research Foundation, Osaka. All other reagents were of the standard grade available and purchased from commercial sources.
Preparation of subcellular fractions from rat uterine smooth muscle. Subcellular fractions of rat myometrium were prepared using the methods of Kidwai et al. (1971) and Janis et al. (1977) with some modifications. Female Sprague-Dawley rats weighing 150-200 g were injected subcutaneously for 2 days with 500,ag/kg of stilbesterol dipropionate (May and Baker Aust. Pty. Ltd., Victoria, Australia) dissolved in peanut oil. They were killed by cervical dislocation and the uteri were rapidly removed, placed in 0.25 M mannitol and 1 mM Tris-EDTA, pH 7.1 at 4°C. For each binding experiment uteri from three rats were pooled and fractionated. The myometrium from uterine horns were carefully separated from the endometrium, minced finely and homogenized with a Potter-Elvehjem homogenizer at 1,200 rpm and 4°C for 2 min. The homogenate was centrifuged at 700 X g for 10 min and the supernatant then centrifuged at 5,000 x g for 10 min. The second supernatant was centrifuged, at 115,000 X g for 40 min to sediment a microsomal fraction which was resuspended in the assay buffer (100 mM KC1, 5 mM MgC12 and 100 mM Histidine, pH 6.8). This resuspended pellet was used routinely as the microsomal fraction for the binding studies.
For subcellular localization of receptors, the resuspended microsomal pellet was layered onto a discontinuous sucrose density gradient (4 ml of 45% sucrose, 3 ml of 33% sucrose, 3 ml of 28% sucrose, and 3 ml of the 8% sucrose loading solution ; sucrose solutions w/w), and centrifuged at 115,000 x g for 90 min. After the centrifugation, the layers were harvested and centrifuged at 115,000 x g for 40 min at 10 mM Tris-HC1 buffer, pH 7.4.
Radiolabeled binding assay. Aliquots of freshly prepared microsomal fracion were incubated in the assay buffer together with 125I-Tyr8-bradykinin in a final volume of 0.5 ml. The protein concentration of the fraction in the incubation medium determined by the method of Lowry et al. (1951) was 100-500 u g/ml. Incubation was performed at 29°C, after which bound and unbound radioactivity was separated by filtration through Millipore filters HAWP 0.45 sum. Radioactivity trapped by filters was counted in an automatic gamma spectrometer at a counting efficiency of 68%. Specific radiolabeled ligand binding was determined by the difference between the radioactivity bound in the absence and in the presence of 1,000-fold excess of unlabeled bradykinin.
The stability of 125I-Tyr8-bradykinin during the incubation with the microsomal fraction of rat myometrium was determined by serial thin layer chromatography of the incubate (n-butyl alcohol : pyridine : acetic acid : water, 15: 10 : 3: 10). The integrity of the radiolabeled ligand was also confirmed by showing no alteration in binding in the presence of the specific kininase II inhibitor, captopril (SQ 14225) up to 10-3 M (E.R. Squibb & Sons, Inc., Princeton, USA). The stability of binding sites under experimental conditions was checked by preincubation of the microsomal fraction.
The activity of 5'-nucleotidase (E.C.3.1.3.5.), used as a marker enzyme of plasma membrane, was measured as described by Song and Bodansky (1967) .
Brad ykinin infusion. In order to determine whether elevation of endogenous circulating bradykinin influences 125I-Tyr8-bradykinin binding sites of rat uterine smooth muscle, rats were infused intravenously for 2 days at a rate of 1p1/hr with 5 x 10-3 M solution of bradykinin (n=4) or vehicle alone (n=4) delivered via osmotic minipumps (Alza, Palo Alto, California, USA) into the jugular vein. This infusion rate lowered the systolic blood pressure of the rats by 8.7+2.4 mmHg (mean±S.E.M., p <0.05). The vascular catheter was inserted subcutaneously, and osmotic minipump was implanted in the interscapular region of the rat's back under anesthesia of pentobarbitone sodium (Abbott Laboratories Pty. Ltd., Australia). The binding assay was assessed 2 days after commencement of the infusions.
RESULTS

1251-Tyr8-bradykinin binding to rat uterine microsomal fraction
Initial experiments indicated that the binding of 125I-Tyr8-bradykinin to the microsomal fraction from rat myometrium was time and temperature dependent. The time course for the binding of 125I-Tyr8-bradykinin to the microsomal fraction at 0°C, 15°C, and 29°C is shown in Fig. l at an initial concentration of 10-9 M of 125I -Tyr8-bradykinin . The equilibrium of binding was reached after 8-10 min at 29°C, after 10-15 min at 15°C and later than 30 min at 0°C.
No change in the thin layer chromatographic patterns of 10-9 M of 125I_ Tyr8-bradykinin incubated at 29°C for 30 min with uterine microsomal fraction was seen, confirming lack of degradation of the radiolabeled ligand. Degradation Estimation of 1251-Tyr8-bradykinin binding parameters
The association rate constant (k1) and the dissociation rate constant (k_1) were calculated from the association curves of '251-Tyr8-bradykinin using final concentrations of 4.7 x 10-10 M and 9.3 X 10-10 M, assuming a second order rate reaction. The association rate constant was 4.8 x 106/M/sec and a dissociation rate constant was 2.4>< 10-3/sec (Fig. 2) . The equilibrium dissociation constant (KD) calculated from these values was 5.0 x 10-10 M. Assuming a pseudo-first order rate reaction for dissociation, a dissociation rate constant of 1.3 X 10-3/sec was calculated from data for the first 5 min of displacement of '251-Tyr8-bradykinin by a 1,000-fold excess of unlabeled bradykinin (Fig. 2) . This value is close to that calculated from the association studies.
The concentration dependence of bradykinin binding studied with 125I-Tyr 8-bradykinin from 2 .0 X 10-10 M to 5.0 X 10-9 M, indicated the presence of more than one class of binding sites (Fig. 3) . The high affinity binding sites were observed up to equilibrium with initial concentrations below 1.2 X 10-9 M. These high affinity binding sites had an apparent dissociation constant of 6.6 X 10-10 M and a capacity of 44.2 fmol/mg protein by Scatchard plot analysis (Scatchard 1949) . The low affinity binding sites noted when using initial concentrations To confirm the validity of the values of KD and binding capacity, the concentration dependence of bradykinin binding was studied with 3H-bradykinin. 3H-Bradykinin ranging from 2 .0 X 10-10 M to 1.2 X 10-9 M was incubated with the same microsomal fraction from rat myometrium under identical conditions. The high affinity binding sites had KD of 6.7 x 10-10 M and a capacity of 51.5 fmol/mg protein. The binding parameters in the same preparation using 1251-Tyr8-bradykinin as radiolabeled ligand were very similar with a KD of 7.1 X 10-10 M and a capacity of 45.1 fmol/mg protein. Binding data from association curves are fitted to second order rate reaction and used to calculate association rate constant (k1) and dissociation rate constant (k_ 1). RL indicates receptorbound ligand complex.
Receptor site (R). Radiolabeled ligand (L). Lower panels show the dissociation of 10 M of initial concentration. After incubation of 10 minutes (at the arrow), unlabeled bradykinin (10-6 M) was added to one set of tubes, and incubation was continued for a further 20 min. The data are fitted to pseudofirst order rate reaction and used to calculate dissociation rate constant (/c_1).
Specificity of 1251-Tyr8-bradykinin binding
The specificity of the bradykinin binding sites was indicated by the lack of binding inhibition in the presence of the unrelated peptides angiotensin I, angiotensin II, Arg8-vasopressin and oxytocin, and by the relationship between binding-inhibition potency and biological activity of a variety of bradykinin analogues. The results are summarized in Fig. 4 . The inhibition of binding by Lys-bradykinin was nearly as efficient as by Tyr8-bradykinin and bradykinin, whereas Met-Lys-bradykinin, Tyr-bradykinin and Tyr 5-bradykinin had significantly less inhibitory effect. The des-Arg9-bradykinin had no inhibitory effect on the binding of 1251-Tyr8-bradykinin up to a concentration of 3 X 10_8 M. Subcellular fractionation and localization of 1251-Tyr8-bradykinin binding Fig. 5 shows the distribution of protein, 5'-nucleotidase activity and specific '251-Tyr8-bradykinin binding among the subcellular fractions. The results are illustrated following the method of De Duve et al. (1955) . The greatest concentrations of both 5'-nucleotidase activity and specific '251-Tyr8-bradykinin binding, occurred in the 115,000 X g pellet after differential centrifugation of 700 X g supernatant. The patterns of 5'-nucleotidase activity and specific 125I_ Tyr8-bradykinin bidning were also closely related after discontinuous sucrose density gradient of a 115,000 X g pellet. These results suggest that the bradykinin Influence of bradykinin infusion on 1251-Tyr8-bradykinin binding Binding parameters by Scatchard plot analysis of 125I-Tyr8-bradykinin binding, ranging from 2 X 10-10 M to 1.2 X 10-s M, to the uterine membranes from rats infused with bradykinin and with vehicle alone, are summarized in Table 1 . 1251 -Tyr8-bradykinin binding capacity was rdecreased after continuous infusion of bradykinin for 2 days. There were no significant changes in the affinity of binding sites. No significant changes were found in wet weight of uterus, protein content and enzymatic activity of the uterine membranes between rats infused with bradykinin and with vehicle (Table 1) .
DISCUSSION
Most studies on bradykinin receptors have relied on indirect information obtained from agonist dose-response curves obtained using in vitro biological preparations. Only limited reports using a direct binding technique are available (Reissmann et al. 1977; Odya et al. 1980 ). Direct binding techniques, similar to those reported here, have many advantages in characterising hormone-receptor In these experiments the initial concentration of 125I-Tyr8-bradykinin was 10-10 M, corresponding to the high affinity binding sites. Each point is the mean from 3 to 6 individual determinations.
Vertical bar indicates S.E.M. We have described here a simple and reproducible method for the study of bradykinin receptors in smooth muscle. In such a study, the characteristic of the radiolabeled ligand selected is critical. We have used the iodinated bradykinin analogues, '251-Tyr8-bradykinin as bradykinin does not contain an amino acid suitable for radioactive labeling by the chloramine T or peroxidase methods. The parent analogue Tyr8-bradykinin has approximately 15% of the activity of bradykinin assessed by the blood pressure dose-response curves in a rat bioassay system. Such activity was not altered by the iodination procedure. It was reported that 1251-Tyr8-bradykinin had only 24% of the activity of bradykinin as measured by the biological response in vitro of the rat uterus (Odya et al. 1980 ). Odya et al. (1980) concluded that 1251-Tyr8-bradykinin was an unsatisfactory ligand because of its susceptibility to kininase II activity (Chin et al. 1975 ). However no evidence of breakdown of the radiolabeled ligand was found under our assay conditions. The absence of kininase II activity was also confirmed by the lack of effect on binding by specific kininase II inhibitor, captopril. Furthermore intact myometrium has been reported to have no kinin degrading properties (Stewart 1979 ). These results suggest that the binding site would be dissimilar to that of kininase II. There may be potential limitations in defining the full characteristics of the hormone-receptor interaction because of the reduced biological activity of Tyr8-bradykinin compared to bradykinin itself. However no difference in the binding characteristics between 1251-Tyr8-bradykinin and 3H-bradykinin which has no significant conformational change was found. In addition, Tyr8-bradykinin and bradykinin behaved identically to the native hormone in the binding inhibition studies. These results support the validity of using '251-Tyr8-bradykinin to characterise bradykinin-receptor interaction in uterine smooth muscle.
Our finding of bradykinin binding sites in microsomal fractions of rat uterine smooth muscle with an apparent KD of 5.0-6.6 X 10-10 M is consistent with data obtained by Reissmann et al. (1977) using an 3H-bradykinin analogue to study binding to plasma membrane from rat uterus. The association of binding sites with 5'-nucleotidase activity in the preparation suggests that the bradykinin recepor is localized to the plasma membrane of the myometrial cells in common with several other peptide hormones (Cuatrecasas 1974; Chang et al. 1975) .
Concentration dependent binding data has suggested the presence of more than one class of binding sites. The dissociation constant of the high affinity binding sites estimated from Scatchard plot analysis, gives a value within the dose-range which produces biological responses (Stewart 1979) . Hence the bradykinin binding sites could act as the cellular receptors for this agonist. The high affinity binding sites with the apparent dissociation constant of 6.6 X 10-10 M were detectable at initial concentrations less than 1.2 X 10-9 M. This is close to the range of agonist activity in rat uterus, the most sensitive target organ and also in the range of circulating concentrations of this hormone (Talamo and Goodfriend 1979) . For these reasons, the high affinity binding sites probably represent the binding sites responsible for mediating agonist activity in this tissue. The low affinity binding sites which appeared to be unsaturable could not be related to any biological effect in this tissue.
Binding inhibition studies suggest that the C-terminal Arg may be critical for binding to the receptor since absence of this residue precludes both binding and biological activity (Stewart 1979 ). The addition of Lys does not effect biological activity and was not shown to impair binding whereas the Met-Lys or Tyrbradykinin showed impaired binding and biological activity. Similarly, internal substitution in Tyr5-bradykinin was associated with a lower affinity of binding than bradykinin.
Thus, these two tyrosine analgoues may not be optimal as radiolabeled ligands in the study of bradykinin binding in this preparation.
The reduced number of bradykinin binding sites seen after prolonged bradykinin infusion suggest that elevated endogenous levels of bradykinin play a role in the bradykinin receptor regulation. This phenomenon is unlikely to be due to receptor occupancy since variations in the occupancy of binding sites by the endogenous hormone should result in a change in the apparent dissociation constant without modification in the total number of receptors. Furthermore since no changes in wet weight of uterus and protein content and 5'-nucleotidase of uterine membrane were observed, the decrease in the number of binding sites can be considered to be attributed to the variations in receptor concentration of the preparation. These findings are consistent with autoregulation theory of receptors described by Raff (1976) .
Thus, receptors mediating the effect of bradykinin on uterine smooth muscle are situated on the plasma membrane similar to receptors for other peptide hormones. Regulation of these receptors is in part under the control of endogenous bradykinin levels. Receptor modification could thus play an independent role in the modulation of bradykinin actions specifically in situations where kinins may be increased.
